How much does it cost to use axitinib/axitinib for one year?

Axitinib/Axitinib is an anti-angiogenesis targeted drug, mainly used for the second-line treatment of advanced renal cell carcinoma. The annual treatment cost is affected by many factors, including medication dosage, drug version (original research or generic), medical insurance reimbursement policy and specific treatment length.

According to the recommended starting dose, axitinib treatment is usually initiated at a dose of 5 mg, and patients need to take it twice a day, approximately 12 hours apart. In clinical application, doctors will adjust the dose according to the patient's specific response, and can be increased to a maximum of 10 mg twice a day.

In China, the original drug of axitinib has been launched and included in the reimbursement scope of Class B medical insurance, which has reduced the financial burden of patients to a certain extent. Common drug specifications include1mg in 14-piece packages and 5mg in 28-piece packages. For example, taking the specification of 5mg*28 tablets as an example, its price is usually more than 200 yuan.

In the international market, the price of the original drug of axitinib is generally high, and usually the price of each box may reach around 600 yuan. In addition, some countries also have generic drugs of axitinib on the market, such as the Laos version, the Indian version and the Bangladesh version. The ingredients of these generic drugs are basically the same as the original drug, and the price is relatively cheap, often selling for about 100 yuan per box. However, prices may change due to factors such as exchange rate fluctuations.

If the patient considers long-term use of axitinib, for example, one year, based on daily dosage, based on 5mg*28 tablets, about twenty boxes will be needed, and the annual cost may be close to more than 60,000 yuan. If you choose to use generic drugs, the cost may be reduced accordingly, with the annual cost being approximately RMB 20,000. However, when choosing, patients still need to pay attention to the quality and legal origin of the medicine to ensure that the treatment is safe and effective.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta